

29 June 2022

BSF Enterprise PLC

Interim Financial Statements

The Board of BSF Enterprise PLC is pleased to announce its Unaudited Interim Financial Statements for the six months ended 31 March 2022, which are available on the Company's website:

www.bsfenterprise.com.

As required under Listing Rule 9.6.1 R, these have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

<https://data.fca.org.uk/#/nsm/nationalstoragemechanism>

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC

Via SEC Newgate below

Geoff Baker – Non-Executive Director

Graham Duncan – Chief Financial Officer

Shard Capital (Broker)

Damon Heath

020 7186 9952

Erik Woolgar

SEC Newgate (Financial Communications)

Bob Huxford

020 3757 6882

Elisabeth Cowell

BSF@secnewgate.co.uk

George Esmond

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims

to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.